Table 2.
Effects of DTT in different populations and outcomes.
| Author | Population | Follow-up length | Cognitive function | Mobility performance | Posture stability |
|---|---|---|---|---|---|
| Pichierri et al., 2011 | MCI, stroke and BI | 2−12 weeks | X | ↑ | ↑ |
| Agmon et al., 2014 | Healthy | 2−4 weeks | X | ↑ | ↑ |
| Law et al., 2014 | Healthy and MCI | 2−60 months | ↑ | N/A | N/A |
| Fritz et al., 2015 | BI, PD and AD. | 12 weeks | ↑ | ↑ | ↑ |
| Lauenroth et al., 2016 | Healthy, MCI, stroke and AD. | 5 years | ↑ | N/A | N/A |
| Wajda et al., 2017 | PD, MS, AD and MCI | 1−12 months | N/A | ↑ | ↑ |
| He et al., 2018 | Stroke | 2 weeks | X | ↑ | N/A |
| Plummer and Iyigün, 2018 | Stroke | 1−6 months | N/A | ↑ | ↑ |
Abbreviations: ↑ = Improve in most studies that analyzed this outcome; X = No effect in most studies that analyzed this outcome; N/A = Not analyzed; BI = Brain injury; PD = Parkinson disease; AD = Alzheimer disease; MCI = Mild cognitive impairment; MS = Multiple sclerosis.